A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7878-7883

  Dickler, Maura N ^a   Rugo, Hope S ^b   Eberle, Careya ^a   Brogi, Edi ^a   Caravelli, Jamesf ^a   Panageas, Katherine S ^a   Boyd, Jeff ^c   Yeh, Benjamin ^a   Lake, Diana E ^a   Dang, Chaut ^a   Gilewski, Teresa A ^a   Bromberg, Jacqueline F ^a   Seidman, Andrew D ^a   D'Andrea, Gabriella M ^a   Moasser, Mark M ^a   Melisko, Michele ^a   Park, John W ^a   Dancey, Janet ^d   Norton, Larry ^a   Hudis, Clifford A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Memorial Health   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; LOPERAMIDE; PACLITAXEL; TAXANE DERIVATIVE; TETRACYCLINE; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ACNE; ADJUVANT THERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSPEPSIA; EPISTAXIS; FATIGUE; HUMAN; HYPERTENSION; LOW BACK PAIN; LYMPHOCYTOPENIA; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; PRURITUS; RASH; SKIN ALLERGY; STOMATITIS; THROMBOSIS; TOXICITY; TREATMENT RESPONSE; VOMITING; BREAST TUMOR; FEMALE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; QUINAZOLINES; TREATMENT OUTCOME;

EID: 59449097074     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0141     Document Type: Article

References (49)

1. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391 -400.
2. Hurwitz H, Fehrenbacher L,Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
4. Yang JC,Haworth L, Sherry RM,et al. Arandomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
5. Burger RA SM, Monk BJ, Greer B, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2005;23:457s.
6. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-24.
7. Miller K, Wang M, Gralow J, et al. Paclitaxel plusbevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
8. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2: 127-37.
9. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plusadjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plusa monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
11. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
12. Shepherd FA, RodriguesPereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
13. Lynch TJ, Bell DW, Sordella R, et al. Activating mutationsin the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
14. PaoW, MillerV, Zakowski M,et al. EGF receptor gene mutationsare common in lung cancers from never smokers and areassociated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
15. Eberhard DA, Huntzicker E, Anderson S. Epidermal growth factor receptor immunohistochemistry (EGFR IHC): assay selection and application to breast cancers. Proc Am Soc Clin Oncol 2002;21:448a.
16. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer ResTreat 2002;71:67-75.
17. Albain K, Elledge R, GradisharW, et al. Open-label phase II, multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer. Breast Cancer ResTreat 2002;76.
18. Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2008.
19. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase in hibitor leads to apoptosis of endothelial cells an dtherapy of human pancreatic carcinoma. Cancer Res2000;60:2926-35.
20. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancercellsbyZD1839 (Iressa),a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res2001;7:1459-65.
21. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Ire-ssa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res2002;62:2554-60.
22. KedarD,BakerCH,KillionJJ,DinneyCP,Fidler IJ. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 2002;8:3592-600.
23. Perrotte P, MatsumotoT, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5:257-65.
24. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapieson the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002;38:1133-40.
25. Li M, Ye C, Feng C, et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res 2002;8:3570-8.
26. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.J Clin Oncol2005;23:7889-96.
27. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/ II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combinaion with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-55.
28. Hainsworth JD, Spigel DR, Farley C,Thompson DS, Shipley DL, Greco FA. Phase II trial of bevacizumab and erlotinib in carcinomasof unknown primary site: The Minnie Pearl Cancer Research Network. J Clin Oncol 2007;25:1747-52.
29. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelinesto evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
30. Simon R. Optimal two-stage designs for phase II clinical trials. Control ClinTrials 1989;10:1 -10.
31. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005;23: 5323-33.
32. Modi S. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 2006;7:270-7.
33. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med 2005; 353:1659-72.
34. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005.
35. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
36. Arteaga CL, O'Neil A, Moulder SL, et al. ECOG1100: a phase I-II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib ('Ire- ssa') in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca). Breast Cancer Res Treat 2004;88:S15-6.
37. Smith IE, Walsh G, Skene A, et al. neoadjuvant anastrozole alone or with gefitinib in early breast cancer: a phase II placebo-controlled trial (study 223) with biological and clinical outcomes. J Clin Oncol 2007; 6578:2006-9.
38. SorlieT, Perou CM,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
39. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
40. Hoadley KWV, Fan C, Sawyer L, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics2007;8:258.
41. Carey L, Rugo H, Marcom P, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008;26.
42. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II Study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25: 4536-41.
43. Miller KD,Trigo JM, Wheeler C, et al. A multicenter phaseII trial of ZD6474,avascular endothelial growth factor receptor-2 and epidermal growth factor recep- tor tyrosine kinase inhibitor,inpatients with previously treated metastatic breast cancer. Clin Cancer Res 2005;11:3369-76.
44. Park JW,KerbelRS, Kelloff GJ, et al.Rationale for biomarkers and surrogate end points in mechanismdriven oncology drug development. Clin Cancer Res 2004;10:3885-96.
45. CristofanilliM,Budd GT, Ellis MJ,et al. Circulating tumor cells, disease progression, and survival in meta- static breast cancer. N Engl J Med 2004;351:781-91.
46. Willett CG, BoucherY, di Tomaso E, et al. Direct evidence that theVEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
47. Rugo H, Dickler M, Scott J, et al. Change in circulating endothelial cells(CEC) and tumor cells (CTC) in patients receiving bevacizumab and erloti- nib for metastatic breast cancer predicts stable disease at first evaluation. Proc Am Soc Clin Oncol 2005;23.
48. Konecny GE, MengYG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10: 1706-16.
49. Pegram MD,Yeon C, Ku NC, GaudreaultJ, Slamon DJ. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibioties directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 2004;88:S124.